{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:20:43Z","timestamp":1788366043895,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shenzhen High-level Hospital Construction Fund"},{"name":"Shenzhen Clinical Research Center for Tuberculosis","award":["20210617141509001"],"award-info":[{"award-number":["20210617141509001"]}]},{"name":"Shenzhen Third People\u2019s Hospital","award":["XKJS-2025013"],"award-info":[{"award-number":["XKJS-2025013"]}]},{"name":"Shenzhen Third People\u2019s Hospital","award":["2025010"],"award-info":[{"award-number":["2025010"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The World Health Organization recommends 1 month of daily rifapentine plus isoniazid (1HP) for tuberculosis preventive treatment (TPT). Real-world safety and feasibility data remain scarce, particularly for East Asian populations, and the performance of fixed-dose 1HP in routine clinical practice requires prospective evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective study at a tuberculosis referral center in Shenzhen, China, enrolling 136 non-human immunodeficiency virus adults (body weight 42\u201390 kg) with tuberculosis infection between October 2024 and July 2025. All participants received fixed-dose 1HP. Outcomes included treatment completion (defined as taking \u226523 doses within 40 days), adverse events graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and 12-hour postdose rifapentine concentrations measured by liquid chromatography-tanden mass spectrometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment completion reached 76.5% (104\/136; 95% confidence interval [CI], 68.7%\u201382.8%). Adverse events occurred in 26.5% of participants, most commonly neutropenia (14.7%) and rash (6.6%); grade \u2265 3 events were observed in only 1.5% (2\/136), both in patients receiving concurrent methotrexate. Median rifapentine concentration was 21.8 mg\/L (interquartile range [IQR], 14.8\u201328.4), and 91.9% of participants exceeded the model-informed 10 mg\/L threshold. Body weight demonstrated a modest inverse correlation with rifapentine concentrations (\u03c1 = \u22120.24; P = .005), accounting for only 7.1% of interindividual variability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fixed-dose 1HP exhibited good tolerability and achieved acceptable completion rate in Chinese adult population. Pharmacokinetic results confirmed adequate rifapentine exposure across the studied weight range, lending support to fixed-dose 1HP for programmatic scale-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag247","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:46:05Z","timestamp":1775821565000},"page":"e386-e394","source":"Crossref","is-referenced-by-count":0,"title":["Fixed-Dose Rifapentine\u2013Isoniazid (1HP) for Tuberculosis Preventive Treatment in Chinese Adults: A Prospective Real-World Safety and Pharmacokinetic Study"],"prefix":"10.1093","volume":"83","author":[{"given":"Senlin","family":"Zhan","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Shenzhen Clinical Research Center for Tuberculosis , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8144-9538","authenticated-orcid":false,"given":"Weijian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Shenzhen Clinical Research Center for Tuberculosis , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Shenzhen Clinical Research Center for Tuberculosis , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Shenzhen Clinical Research Center for Tuberculosis , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0296-1626","authenticated-orcid":false,"given":"Tian","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Department of Pharmacy, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2479-3327","authenticated-orcid":false,"given":"Guofang","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Shenzhen Clinical Research Center for Tuberculosis , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Shenzhen Clinical Research Center for Tuberculosis , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7511-901X","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Department of Pharmacy, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-0228","authenticated-orcid":false,"given":"Peize","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen, Guangdong Province ,","place":["China"]},{"name":"Shenzhen Clinical Research Center for Tuberculosis , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2026090211565348900_ciag247-B1","volume-title":"Global tuberculosis report 2025","author":"World Health Organization (WHO)","year":"2025"},{"key":"2026090211565348900_ciag247-B2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026090211565348900_ciag247-B3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"2026090211565348900_ciag247-B4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090211565348900_ciag247-B5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026090211565348900_ciag247-B6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2026090211565348900_ciag247-B7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.cmi.2024.06.024","article-title":"One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV population: a randomized controlled trial","volume":"30","author":"Huang","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026090211565348900_ciag247-B8","volume-title":"WHO Consolidated guidelines on tuberculosis: module 1: prevention\u2014tuberculosis preventive treatment","author":"World Health Organization (WHO)","year":"2024","edition":"2nd ed"},{"key":"2026090211565348900_ciag247-B9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","article-title":"Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection","volume":"202","author":"Hibma","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026090211565348900_ciag247-B10","doi-asserted-by":"crossref","first-page":"e01964-18","DOI":"10.1128\/AAC.01964-18","article-title":"A population pharmacokinetic analysis shows that arylacetamide acetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine","volume":"63","author":"Francis","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026090211565348900_ciag247-B11","doi-asserted-by":"crossref","first-page":"e643","DOI":"10.1093\/cid\/ciaf404","article-title":"Safety, feasibility and rifapentine plasma concentration in Chinese children with 1 month of daily rifapentine plus isoniazid for tuberculosis infection","volume":"81","author":"Liu","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026090211565348900_ciag247-B12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/jac\/dkaf029","article-title":"Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection","volume":"80","author":"Liu","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026090211565348900_ciag247-B13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"2026090211565348900_ciag247-B14","first-page":"862","article-title":"Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis","volume":"8","author":"Langdon","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026090211565348900_ciag247-B15","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","author":"National Cancer Institute","year":"2017"},{"key":"2026090211565348900_ciag247-B16","doi-asserted-by":"crossref","first-page":"e1004758","DOI":"10.1371\/journal.pmed.1004758","article-title":"Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: the Ultra-Curto randomized controlled trial","volume":"23","author":"Durovni","year":"2026","journal-title":"PLoS Med"},{"key":"2026090211565348900_ciag247-B17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11095-007-9407-0","article-title":"Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates","volume":"25","author":"VanWert","year":"2008","journal-title":"Pharm Res"},{"key":"2026090211565348900_ciag247-B18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026090211565348900_ciag247-B19","first-page":"Cd000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2013","author":"Shea","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag247\/68069905\/ciag247.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/2\/e386\/68069905\/ciag247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/2\/e386\/68069905\/ciag247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:57:37Z","timestamp":1788364657000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/2\/e386\/8653226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag247","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,4,13]]}}}